in this NPR Op-Ed, Josh Eibelman '20 describes how millions of individuals suffering from Alzheimers that are not fluent in English are barred from participating in clinical trials to treat Alzheimers.
"According to interviews with doctors, government officials and pharmaceutical companies, few Alzheimer's studies include medical interpreters to help patients complete the specialized neuropsychological testing component required," Eibelman writes.
Continue reading the full article on the NPR website.